A New Approach to Challenging Targets
Harnessing AI-driven computational chemistry to develop small molecule therapeutics in diseases with high unmet need
ACE-2223
Our lead program, ACE-2223, is a small molecule designed to specifically target aggregated TDP-43 and restore its function, which is central to the pathology of progressive neurological disorders like ALS and FTLD. By disassembling the misfolded, aggregated form of this protein, ACE-2223 aims to interrupt the cascade of cellular dysfunction that drives disease.
Our Team
Our team brings together deep expertise in drug discovery, computational science, and pharmaceutical development, united by a shared commitment to advancing rigorous science and accelerating meaningful treatment options for patients.
Pipeline & Platform
Resolute is Acelot's state-of-the-art integrated drug-discovery platform. It has been developed to tackle historically challenging protein targets for therapeutic intervention, using modern artificial intelligence technology and proprietary computational chemistry methodology. The platform has been successfully deployed to date on several projects to generate high-quality first-in-class drug candidates.